|
|
Article: BrainStorm Cell Therapeutics Enters into Agreement for Clinical-Grade Stem Cell Production for ALS.
- Article from:
- Business Wire
- Article date:
- August 31, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK & PETACH TIKVAH, Israel -- BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into an agreement with Protein Production Services Ltd. (PPS), a leading manufacturing contractor, in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic product. The clinical-grade product will be used in a pre-clinical safety trial for the company's innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's disease).
"We are very excited that we are moving into this phase of product development with a ...